close



Forgotten your password?
New user? Register here
 
Pharma Industry News
Printable Version   Email to a friend

Savings Help the Medicine Go Down

Prescription drug coverage for low income seniors reduces Medicaid

WALTHAM, Mass., June 24, 2008—A new study of state-subsidized pharmacy assistance programs showed that providing prescription drug coverage for low-income seniors reduces Medicaid and Medicare costs. Moreover, needy seniors enrolled in the programs were able to cut their dose skimping and nursing home admissions in half, according to the Brandeis University research.

In 2002, Illinois and Wisconsin implemented state pharmacy assistance programs with joint federal funding. Senior citizens with incomes below 200 percent of the federal poverty level, but not eligible for Medicaid, could join. The Brandeis study evaluated whether these "SeniorCare" programs increased access to prescription drugs and reduced Medicaid enrollment, said lead author Donald Shepard, a health economist at the Heller School for Social Policy and Management at Brandeis.

The study matched 7,699 Illinois and 1,798 Wisconsin so called "buy-in" beneficiaries to similar Ohio controls because the states share many similarities. Since Illinois already had a different prescription program in place its SeniorCare program did not reduce the number of seniors enrolling in Medicaid, but it did reduce how many were admitted to nursing homes and how much enrollees spent on drugs.

For example, in the first year of the Illinois program, nursing home entry was 2.4 percent, compared to 4.4 percent for the Ohio controls. Likewise, Medicaid spending averaged $631 over Illinois SeniorCare members, versus $1,605 for Ohio controls, a savings of 61 percent. The study showed that these savings fell slightly short of the state's first-year program costs of $1,394 per enrollee.

In Wisconsin, SeniorCare members joined Medicaid at half the rate of the Ohio controls, and had half the rate of nursing home entry. Medicaid spending per enrollee was 81 percent lower than in Ohio. Finally, in Wisconsin, savings exceeded the state's first-year costs per enrollee of $1,032.

"Our study demonstrates the real value of easily understood drug assistance programs for vulnerable seniors," said Shepard. "Needy elders in both states benefited from the outreach, public subsidies and straightforward design. Medicare Part D plans with similar features might well reduce nursing home admissions and achieve Medicaid savings nationally."

###
Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
August 14, 2008
Audience: Cardiologists, hospital risk managers [Posted 08/14/2008] Boston Scientific and FDA informed healthcare professionals...
August 12, 2008
Audience: Primary healthcare physicians, internists, other healthcare professionals[Posted 08/12/2008] FDA informed healthcare...
August 12, 2008
Audience: Pain management specialists, risk managers, other healthcare professionals, patients[UPDATED 08/12/2008] Watson...
August 8, 2008
Audience: Oncologists, other healthcare professionals[Posted 07/31/2008] FDA informed healthcare professionals of modifications...
More...
Latest Drug Information Updates

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

More...